Response to treatment of 24 evaluable patients with PTCL
| Response parameter . | Histopathology, proportion . | Total no. (%) . |
|---|---|---|
| CR | ||
| PTCL-U | 7/14 | 17 (70.8) |
| AILD-T | 6/6 | — |
| ALCL | 3/3 | — |
| EATCL | 1/1 | — |
| PR | ||
| PTCL-U | 1/14 | 1 (4.2) |
| Minor response | ||
| PTCL-U | 1/14 | 1 (4.2) |
| Disease progression | ||
| PTCL-U | 5/14 | 5 (20.8) |
| Patients alive | ||
| PTCL-U | 5/14 | 14 (58.3) |
| AILD-T | 6/6 | — |
| ALCL | 3/3 | — |
| Median follow-up, mo (range) | — | 16 (5-42) |
| Patients alive in CCR | ||
| PTCL-U | 5/14 | 13 (54.2) |
| AILD-T | 5/6 | — |
| ALCL | 3/3 | — |
| Median follow-up, mo (range) | — | 11 (5-42) |
| Response parameter . | Histopathology, proportion . | Total no. (%) . |
|---|---|---|
| CR | ||
| PTCL-U | 7/14 | 17 (70.8) |
| AILD-T | 6/6 | — |
| ALCL | 3/3 | — |
| EATCL | 1/1 | — |
| PR | ||
| PTCL-U | 1/14 | 1 (4.2) |
| Minor response | ||
| PTCL-U | 1/14 | 1 (4.2) |
| Disease progression | ||
| PTCL-U | 5/14 | 5 (20.8) |
| Patients alive | ||
| PTCL-U | 5/14 | 14 (58.3) |
| AILD-T | 6/6 | — |
| ALCL | 3/3 | — |
| Median follow-up, mo (range) | — | 16 (5-42) |
| Patients alive in CCR | ||
| PTCL-U | 5/14 | 13 (54.2) |
| AILD-T | 5/6 | — |
| ALCL | 3/3 | — |
| Median follow-up, mo (range) | — | 11 (5-42) |
— indicates not applicable.